

Is the BRCA Germline Mutation a Prognostic Factor in Korean Patients with Early-onset Breast Carcinomas?

Doo Ho Choi, M.D.*, Min Hyuk Lee, M.D.[†] and Bruce G. Haffty[†]

Departments of *Radiation Oncology and [†]Surgery, Soonchunhyang University, College of Medicine, Seoul, Korea,
[†]Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA

Purpose: The purpose of this study was to determine if there were prognostic differences between BRCA related and BRCA non-related Korean patients with early-onset breast carcinomas.

Materials and Methods: Sixty women who had developed breast cancers before the age of 40, and who were treated at the Soonchunhyang University Hospital, were studied independently of their family histories. The age range was 18 to 40 with a median of 34.5 years. Lymphocyte specimens from peripheral blood were studied for the heterozygous mutations of BRCA1 and BRCA2 using direct sequencing methods. Immunohistochemistry was performed on the paraffin-embedded tissue blocks that were available.

Results: Eleven deleterious mutations (18.3%, 6 in BRCA1 and 5 in BRCA2) and 7 missense mutations of unknown significance (11.7%), were found among the 60 patients. More than half of the mutation were novel, and were not reported in the database. Most of the BRCA-associated patients had no history of breast cancer. No treatment related failures were observed in the BRCA carriers, with the exception of one patient that had experienced a new primary tumor of the contralateral breast. The seven year relapse free survival rate were 50 and 79% in the BRCA carrier and BRCA negative patients, respectively. Although the expression of estrogen and progesterone receptors were less common, and histological features more aggressive, in the BRCA associated tumors, the outcome of the patients with BRCA mutations was not poorer than that of the patients without deleterious mutations.

Conclusion: Despite the BRCA mutation carriers having adverse prognostic features, the recurrence rate was relatively lower than that in the BRCA non-carrying Korean patients with early-onset breast carcinomas. In addition, although the prevalence of the BRCA mutation in Korean patients was higher than that in white patients, the penetrance of the cancer seemed to be relatively low in Korean women carrying BRCA mutations. A large population based study of the BRCA mutation, with a long-term follow-up of the study patients will be required to confirm these results.

Key Words: BRCA mutation, Early-onset breast carcinoma, Prognostic factor, Korean

Introduction

Breast cancer is the most common malignancy in female,

Part of this work was presented at 25th San Antonio Breast Cancer Symposium (2002).

This work was partly supported by the Greenwich Breast Cancer Alliance and Ethel F. Donaghue Women's Health Investigator Program at Yale.

Submitted March 7, 2003 accepted May 26, 2003

Reprint request to Doo Ho Choi, Department of Radiation Oncology, Soonchunhyang University Hospital, Seoul, Korea

Tel: 02)709-9412, Fax: 02)709-9414

E-mail: dohochoi@hosp.sch.ac.kr

occurring in approximately one in eight women in western countries. But the incidence and age patterns of breast cancer varies widely between countries.¹⁾ About 25% of invasive breast cancer cases in Korea occur in patients younger than 40 (National Cancer Registry Center in Korea 2000) in contrast to 4~8% of total cases occur in the same age group in western countries.

The breast carcinoma susceptibility genes BRCA1 and BRCA2, has been extensively investigated since its isolation from breast cancer patients with family history in 1994 and 1995.^{2,3)} Through genetic linkage analysis, BRCA1 was localized to 17q21. The BRCA1 gene contains 22 exons distributed over more than 100kb of genomic DNA and encodes for a protein of 1863 amino acids. BRCA2 has been identified on chromosome 13q12~13 and likely

accounts for a large proportion of non-BRCA1 familial breast cancer. Many mutations has been described with the majority resulting in a truncated protein.⁴⁾

Inherited mutations in the BRCA1 and BRCA2 put women at high risk for developing breast cancer at a relatively early age. Early-onset breast cancer (diagnosed before menopause) is considered an important feature of inherited susceptibility. Women who carry mutations in these genes have a significantly increased chance of developing breast cancer before the age of 50 between 33% and 50%.⁵⁾ Young women with breast cancer have more aggressive lesions manifested by an elevated S-phase fraction, abnormal p53 expression and higher hormone receptor negativity. Eisinger et al. noted that histologic grade appeared to segregates as a genetic trait, thus establishing a genotype-phenotype correlation.⁶⁾ Others report distinct molecular pathogenesis of early-onset breast cancers in the BRCA1 and BRCA2 mutation carriers.^{7,8)}

Currently molecular studies of the BRCA1 or BRCA2 mutations has been focused within North America or western countries, especially in Caucasian populations. The prevalence of the BRCA1 and BRCA2 mutation were in the range of 5~15% in young women with breast cancer and three specific mutations are frequent especially Ashkenazi descendant in Jews.^{9,10)} Similar data pertaining to Asian populations remain limited except a few about Japanese and Chinese.^{11,12)} There is only one article about BRCA1 and BRCA2 study of Korean women, but it is focused on the identification of the BRCA mutation in patients with strong familial history of breast and/or ovarian cancer.¹³⁾

During the study of BRCA mutation status in Korean women with early-onset breast cancer regardless of family history, we found higher incidence of the BRCA1 and BRCA2 mutation (not published data). Despite adverse tumor characteristics, some studies reported that patients with the BRCA-associated tumor did not have poor disease free and overall survival rate and higher local failure than those in patients with sporadic breast cancer.⁷⁾ other studies reported the BRCA mutation as a poor prognostic factor.¹⁴⁾ The purpose of this study was to determine if there were prognostic differences between BRCA related and BRCA non-related Korean patients with early-onset breast carcinoma.

Materials and Methods

Sixty patients were selected among patients with breast carcinoma that was diagnosed with the age of 40 or younger who were treated at the University Hospital, Seoul, Korea from 1995 to 2000 from hospitals breast cancer registry. None of the

patients were selected solely based on a family history of breast cancer or ovarian cancer. Four patients treated before 1995 were included among the 60 patients. The median and range for the ages of onset were 34.5 and 22~40 years. Twenty-seven patients underwent breast conservative surgery and radiotherapy and 33 patients underwent modified mastectomy or skin-sparing mastectomy. All of the patients received postoperative chemotherapy and patients with hormone receptor positive tumor received tamoxipen therapy.

They all were invited to participate this study and informed consent was obtained from all subjects. They were informed of the possibility that testing could lead to psychological distress and family disruption, but it could also identify those at risk, thus warranting increased surveillance or preventive options that might result in improved health care. All patients were told that the results would be kept in locked coded search files and would not become part of their clinical records.

Blood samples were obtained from phlebotomy in 2 tubes from each patient. After collecting blood samples of 15~20 patients in a day, we sent it instantly to professor Haffty's laboratory in Yale University Hospital, USA via air borne express mail. We repeated this procedure several times to collect samples of 60 patients with breast cancer. And 31 paraffin embedded tissue blocks were available from the hospital archives.

1. Genetic testing

Genomic DNA was isolated from peripheral blood lymphocytes. All analyses of the BRCA1 and BRCA2 were performed by direct gene sequencing at Myriad Genetics Laboratories, Salt Lake City, UT, USA. Aliquotes of patients DNA were each subjected to polymerase chain reaction (PCR) amplification of entire coding region and intro-exon boundaries (35 reactions for BRCA1, 47 reactions for BRCA2). The amplified products were each directly sequenced in forward and reverse directions using fluorescent dye-labeled sequencing primers. Chromatographic tracing of each amplicon was analyzed by a proprietary sequence analysis software followed by visual inspection and confirmation.

Genetic variants were detected by comparison with a consensus wild-type sequence constructed for each gene and were confirmed by repeated analysis, including PCR amplification of the indicated gene regions and sequence determination.

Positive for a deleterious mutation includes all mutations (nonsense, insertions, deletions) that prematurely terminate the protein product of BRCA1 at least ten amino acids from C-terminus, or the protein product of BRCA2 at least 110 amino acids from C-terminus. In addition, specific missense mutations

and non-coding intervening sequence (IVS) mutations are recognized as deleterious on the basis of data, functional assays, biochemical evidence and demonstration of abnormal mRNA transcript processing. Genetic variant, suspected deleterious include genetic variants indicates a likelihood that the mutation is deleterious. Genetic variant of uncertain significance include all missense mutations that occur in analysed intronic regions and mutations that truncate BRCA1 and BRCA2 distal to amino acid positions 1853 and 3195, respectively.

2. Immunohistochemistry

Five μm sections cut from paraffin blocks were dried at 60°C for 1 hour. The section were dewaxed in xylene and rehydrated through graded alcohols to distilled water. Antigen retrieval used was steam bath at 97°C for 20 minutes for determination of ER, PR, and Her-2/neu. Dako autostainer was used to for the staining and no blocking steps were required. The sections were incubated in primary antibody at various dilutions for 30 minutes at room temperature. Secondary antigen retrieval was performed using detection kits (Envision for ER and PR, Dako Lsab+ and Hercep Test for Her-2/neu). All sections were counterstained with hematoxylin, dried and coverslipped.

Tumors known to express the 3 markers served as positive control. For HER-2/neu, primary antibody was omitted for negative control and DAKO K5204 was used for reference grade. A cut-point of $\geq 10\%$ tumor cells stained without considering intensity was used to categorize positive results for ER and PR. For HER-2/neu, only membrane staining was scored positive and cytoplasmic staining was ignored. A numeric score ranging from 0 to 3 that reflects the staining intensity and patterns in 10% or more of tumor cell is employed. Numeric score 2+ or 3+ was considered positive by Hercep Test guideline. All immunostained section were examined and scored by two of the authors. Any discrepancies were resolved by subsequent consultation to breast pathologist, D. Carter, in the Yale University Hospital.

After completion of the study, we reviewed all the medical chart including pathology reports and immunohistochemistry reports. Some of the immunohistochemistry data not available in this tissue block study were included in this analysis. Details of family history of cancer were repeatedly obtained during renewed contact and follow-up for notifying the test results.

3. Statistical analysis

All the patient data including clinical immunological and BRCA

Table 1. Clinical Characteristics of 60 Patients

Characteristics	Total no. (n=60)	BRCA1/2 carrier (n=9)	BTCA1/2 (-)* (n=51)	p-value
Age at Dx (years)				
< 35	35	5	30	
36~40	25	4	21	NS*
Median age	34.5	34	35	
Tumor histology				
Infiltrating ductal	55	9	46	
Medullary	3	0	3	
Tubular	1	0	1	NS
Mucinous	1	0	1	
Tumor size				
T1	31	3	28	
T2	26	6	20	NS
T3	2	0	2	
Lymph node involvement				
Yes	27	4	23	NS
No	33	5	28	
Nuclear grade				
GI (most anaplastic)	17	4	13	
GII	32	4	27	NS
GIII	1	1	0	
no data	10			
Family history of br or ov (1st and 2nd degree)	8	2	6	NS

*Including BRCA mutation with variant of uncertain significance. NS[†]: non significant

mutations were entered into a computerized database employing SPSS (Statistical Package for the Social Science). Differences in categorical variables between wildtype (and genetic variant of uncertain significance) and mutations were compared using standard chi-square analysis or Fishers exact test, as appropriate. For analysis of extent of bivariate correlations, Pearson's Correlation Coefficients were used. We used Kaplan-Meier to calculate relapse free survival probabilities and the log-rank test was used to compare survival distributions of cases with and without deleterious germline mutations.

Results

Characteristics of patients and tumors of the BRCA-associated and sporadic breast cancers are summarized in Table 1. We included patients with BRCA missense mutation (variants with uncertain significance) into the BRCA non-carrier cohorts for convenience of analysis. Infiltrating ductal carcinoma was the predominant histology in both groups and 3 medullary carcinoma in the study belonged to women without mutations. One patient with bilateral disease and two patients with primary tumors larger than 5.0 cm were also noted in women without mutation. Four of the 9 BRCA carrier had lymph node metastasis, but none of them had 4 or more lymph node metastasis.

Deleterious germline BRCA mutation were detected in 9 patients (15%) with 11 mutations (18.3%, 6 in BRCA1 and 5 in BRCA2). Sequence variants with uncertain significance were detected in seven of 60 participants including 2 patients with coincidental deleterious mutations. Six of 11 deleterious mutations and 4 of 7 missense mutations were novel mutation, native to Korean up to date and they were not previously reported in the Breast Cancer Information Core database. The median onset age for BRCA mutation carriers was similar to that of mutation negative cases.

Three patients had more than 2 sequence variants including 2 patients with deleterious double heterozygotes mutations (Table 2). Patient with ID# 60071 had two deleterious mutations, one




Fig. 1. BRCA1 E1661X figure. Mutation sequence change in central area (G→T) from the wt (wild type) to del (deleterious mutation) resulted in stop codon by F (forward) and R (reverse) directions.

Table 2. Details of Cases with 2 or More Mutations in BRCA1 and BRCA2 Genes

ID	Age	Mutation	Gene	Site	Citation*	Type	FH [†]	FH [‡]
60071	33	E1661X	BRCA1	Exon 17	Novel	Nonsense	No	Stomach
60351	26	6174del4	BRCA2	Exon 11	(8)	Frameshift	No	Larynx Stomach
		1635del5	BRCA1	Exon 11	(17)	Frameshift		
60261	37	3026delCA	BRCA2	Exon 11	Novel	Frameshift	No	Leukemia Leukemia
		M1628T	BRCA1	Exon 16	(39)	Missense		
		1775delT	BRCA2	Exon 10	Novel	Frameshift		
		K1533N	BRCA2	Exon 11	Novel	Missense		

Citation*: Citation number in Breast Cancer Information Core database, FH[†]: Family history of breast or ovarian cancer in the 1st and 2nd relatives, FH[‡]: Family history of other cancer

of them is the germline BRCA1 nonsense mutation E1661X, resulting in premature truncation of the BRCA1 protein at amino acid position 1661 (Fig. 1). All of the 3 patients had no history of breast or ovarian cancer in their first or second relatives. In fact, there was a significant absence of a family history of breast or ovarian cancer in many of the patients with mutation. Only two of nine deleterious mutation carrier had family history of BRCA-related cancer, and this result is not different from the incidence of family history of BRCA-related cancer in the BRCA negative patients and patients with missense mutation of uncertain significance (6/51).

For immunohistochemistry, BRCA-associated tumors were shown to have less estrogen, progesterone receptor. Pearson's correlation coefficient between the BRCA positivity and estrogen receptor negativity was -0.333 and the negative correlation was statistically significant at the 0.05 level ($p=0.038$). Although statistically not significant, nuclear grade I (most anaplastic) was more frequently observed in the BRCA associated tumors (4/9) than in the tumors of BRCA non-carrier (13/41). None of the BRCA mutation carriers, studied by Hercep Test ($n=5$) had HER-2/neu positivity while BRCA negative (including missense mutation of uncertain significance) were shown to have 38% positivity ($p=0.092$).

Five year relapse free survival rate was 92% for T1 and 67% for T2 and this difference was statistically significant ($p=0.0412$) (Fig. 2). Statistically significant relapse free survival difference was not observed according to axillary lymph node status (data not shown), but the survival difference was strongly observed by subdividing axillary metastasis into one to three positive group and 4 or more positive group (Fig. 3). Among the patients not

associated with BRCA mutations ($n=51$), three experienced local recurrence and four had distant metastasis as the first event. In contrast, no one out of the nine BRCA mutation carrier had loco-regional failure or distant metastasis. Only one patients with BRCA mutation carrier experienced new primary cancer in the contralateral breast 6 and half years after treatment. She had estrogen receptor negative tumor and received 6 cycles of CMF chemotherapy without tamoxipen therapy. The 7 year event free survival rate was 79% for BRCA non-carrier and 50% for BRCA carrier, and the difference was statistically not significant (Fig. 4).

Statistically significant survival differences were not observed according to estrogen and progesterone receptor, nuclear grade, HER-2/neu status.




Fig. 2. Event free survival rates according to T-stage.




Fig. 3. Event free survival rates according to status and numbers of axillary lymph node.




Fig. 4. Event free survival rate according to BRCA status (BRCA negative includes missense mutation of uncertain significance).

Discussion

Recently, Kang et al. reported existence of the BRCA1 and BRCA2 germline mutation in Korean patients with multiple family history of breast cancer or ovarian cancer.¹³⁾ In this study of Korean women with early onset breast cancer, the prevalence of 11 mutations (18.3%) and 9 cases (15%) out of 60 patients was highest among outbred populations in the published series and no recurrent founder mutation was observed.

There were two groups of races who had higher prevalence of the BRCA-associated cancer than that of this study. Results carried out in isolated populations such as Ashkenazi Jews¹⁰⁾ or Icelanders^{16,17)} showed that the prevalence of the BRCA-associated breast tumors in young patients is about 30% for Ashkenazi Jews and about 25% for the Icelanders. In those inbred populations, individual, highly recurrent founder mutations account for the majority of all mutations. Over 2% of Ashkenazi Jews carry mutations in the BRCA1 (185delAG, 5382insC) and 6174delT in the BRCA2 and about 0.5% of Icelanders have 999del5 in the BRCA2 gene. Among Ashkenazi Jews, BRCA1 mutations appear to make a greater contribution to early-onset breast cancer than do BRCA2 mutations. Conversely in Iceland, BRCA2 accounts for a major portion and BRCA1 makes a very small contribution. Therefore, the results derived from such populations are not comparable to outbred populations.

In the other series, most of them have outbred populations, the prevalence rate of the BRCA1 and BRCA2 mutations lie between 6 and 12%.^{18~26)} Mutations in the 2 genes make approximately equal contributions to early-onset breast cancer in this study. This is consistent with other results in outbred populations. Approximately equal numbers of the families had numbers in the BRCA1 and BRCA2 genes by the Breast Cancer Linkage Consortium of families with breast cancer only.²⁷⁾ One study had a large proportion of the BRCA1 mutation, because they include missense mutations in the analysis, and all of the missense mutations were BRCA1 genes.²³⁾ The BRCA2 gene mutations contributed more than the BRCA1 mutation to breast in the Philippines.²⁵⁾ The Philippines consists of many islands, and they also had many common founder mutations in the BRCA2 gene.

One of the most important findings of this study is that most of the patients with BRCA do not have family history of breast or ovarian cancer. We observed only 2 cases out of 9 patients have family history, one from her mother and the other from her paternal aunt. The observation that seven of nine carriers

do not have a relative with breast or ovarian cancer is nevertheless in accordance with previous studies. Family history is observed more than 80% of cases in the Ashkenazi and Icelandic,^{10,16)} 40~90% in the other populations.^{19~23,25)} Only one study with ethnic Chinese had similar family history pattern to this study.²⁶⁾ It could mean that mutations observed in Korean or Chinese confer a lower penetrance than previously estimated in western countries especially in Ashkenazi population. Early studies of families with multiple cases of breast and ovarian cancer suggested that BRCA1 mutation carriers may have a lifetime breast risk of up to 84% and ovarian risk of up to 44%.²⁷⁾ However, studies of less selected families have suggested that the risk may be somewhat lower than those initial estimates,⁵⁾ and the penetrance of the BRCA2 mutation is lower than that of the BRCA1 mutation, especially in Jewish population.^{28,29)} Therefore, mutations in Korean population may have lower susceptibility or lower risk site mutations to breast cancer than those in western European ancestry through genetic and environmental modifying effects.

The identification of a histologic pattern characterizing BRCA associated breast cancer has not been conclusive, but many have noted an excess of medullary histology was observed (19% vs 0%) in a series of the BRCA1-associated breast cancers compared to sporadic cases in a study from France,³⁰⁾ in a carriers from the Breast Cancer Linkage Consortium, and among women with early-onset breast cancer in a population-based study,³¹⁾ suggesting that medullary histology itself may be an indication for the BRCA1 testing. In this study of Korean women with early-onset breast carcinoma, all the three patients with medullary histology belonged to the BRCA non-carrier.

The phenotypic expression of the BRCA1 and 2 breast cancer indicates distinctive prognostic features. The Breast Cancer Linkage Consortium examined histopathologic features of breast cancer in women with the BRCA1 mutations and, when compared to controls, showed an excess of high grade tumors, high mitotic rates as well as higher rates of aneuploidy and high proliferative fraction in the BRCA1 carriers. Another case control study among women of Jewish descent found that the BRCA1-associated tumors were significantly more likely to be high grade and estrogen receptor negative.¹⁰⁾

For immunohistochemistry study, results from this study are not different from others. BRCA mutation carriers are typically estrogen receptor negative, progesterone receptor negative and HER-2/neu negative in all age groups from tumors with family history,^{10,14)} but similar results were observed in the early-onset breast cancer regardless of family history and mutation sites.^{26,31)} These data suggest that neither hormone receptor nor Her-2/neu

stimulation seem to be important in the pathogenesis of cancers arising in women with the BRCA mutation carrier.

Despite these distinctive histologic and immunohistochemical features, the identification of the BRCA-associated tumor as a prognostic factor has been elusive. In accordance with poor prognostic features noted histologically with for the BRCA1-related breast cancer, 2 European studies reported survival rates that were similar to or worse than sporadic cases, with a significantly increased risk of contralateral breast cancer.^{7,32,33} One report failed to find a higher rate of local, regional, or distant metastasis among young women treated with breast conserving surgery and radiation therapy whose family history suggestive of hereditary breast compared to a group without a significant family history.³⁴ Gaffney et al. also reported that despite their younger age at presentation, BRCA mutation carriers presented at a similar stage, display a normal acute reaction to radiotherapy and similar prognosis when compared with sporadic breast cancer patients in the Utah Cancer Registry.³⁵ Another study found that survival of 43 BRCA1 carriers with advanced ovarian cancer was significantly better than that of matched sporadic cases, median survival was 77 months in the BRCA1 carriers versus 29 months in noncarriers.³⁶ In contrast, a population based study from Sweden noted an initial survival advantage in BRCA-associated cases, but this advantage did not persist over time.³² Studies of prognosis of the BRCA2-associated breast cancer have not shown evidence for substantial differences in comparison with sporadic breast cancer.³⁷ In this study, all of the cases with the BRCA non-carriers and 4 or more axillary lymph node metastasis may cause poor outcome in the BRCA negative groups of patients.

Further large studies with appropriate control populations and long-term follow-up will be required to determine whether the BRCA mutation status is prognostic factor or not.

In conclusion, Korean patients with early-onset breast cancer have characteristics of high prevalence of the BRCA mutations, low family history. Despite of poor prognostic features, patients with the BRCA mutation did not have poor outcome. A large population based screening of the BRCA mutation with a long-term follow-up of the study patients will be required to establish the frequency, penetrance and prognostic significance of the BRCA mutation.

References

1. Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. IARC Scientific Publications No. 143. Lyon: IARC, 1997
2. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66-71
3. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995;378:789-792
4. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in BRCA1 breast and ovarian cancer susceptibility gene. *J Am Med Assoc* 1995; 273:535-541
5. Struwing JP, Hange P, Wacholder S. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997;336:1401-1408
6. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Naguchi T, Baily C. Germline mutation at BRCA1 affects the histologic grade in hereditary breast cancer. *Cancer Res* 1996;56:471-474
7. Verhoog LC, Brekelmans CTM, Seynaeve C, et al. Survival and tumor characteristics of Breast cancer patients with germline mutations of BRCA1. *Lancet* 1998;351:316-321.
8. Armes JE, Trute L, White D, et al. Distinct molecular pathogenesis of early onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population based study. *Cancer Res* 1999;59:2011-2017
9. Clause EB, Schildkraut JM, Thompson WB. The genetic attributable risk of breast and ovarian cancer. *Cancer* 1996; 77:2318-2324
10. Robson M, Gilewski T, Haas B, et al. BRCA-associated breast cancer in young women. *J Clin Oncol* 1998;16:1642-1649
11. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2- associated hereditary breast carcinoma in Japanese women. *Cancer* 1999;85:2200-2205
12. Sng JH, Chang J, Feroze F, et al. The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives. *Br J Cancer* 2000; 82:538-542
13. Kang HC, Kim IJ, Park JH, et al. Germline mutations of BRCA1 and BRCA2 in Korean breast families. *Hum Mutat* 2002;20:235-239
14. Johannson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. *Eur J Cancer* 1997;33:362-371
15. Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. *Am J Hum Genet* 1997;60:505-514
16. Johannesdottir G, Gudmundsson J, Berthorsson JT, et al. High prevalence of the 999del5 mutations in Icelandic breast and ovarian cancer patients. *Cancer Res* 1996;56: 3663-3665
17. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study

- of a single BRCA2 mutation with high carrier frequency in a small population. *Am J Hum Genet* 1997;60:1079-1084
18. **Malone KE, Daling JR, Neal C, et al.** Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. *Cancer* 2000;88:1392-1402
 19. **Anton-Culver H, Cohen PF, Gildea ME, Ziogas A.** Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. *Eur J Cancer* 2000;36:1200-1208
 20. **Peto J, Collins N, Barfoot R, et al.** Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. *J Natl Cancer Ins* 1999;91:943-949
 21. **English Breast Cancer Group.** Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. *Br J Cancer* 2000; 83:1301-1308
 22. **Papelard H, de Bock GH, van Eijk R, et al.** Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. *Br J Cancer* 2000;83:719-724
 23. **Loman N, Johannson O, Kristoffersson U, Olsson H, Borg A.** Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. *J Natl Cancer Ins* 2001;93: 1215-1223
 24. **Southey MC, Tesoriero AA, Anderson CR, et al.** BRCA1 mutations and other sequence variations in a population-based sample of Australian women with breast cancer. *Br J Cancer* 1999;79:34-39
 25. **Matsuda ML, Liede A, Kwan E, et al.** BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. *Int J Cancer* 2002;98:596-603
 26. **Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC.** Pathologic features and BRCA1 mutation screening in premenopausal breast cancer patients. *Clin Cancer Res* 2001; 7:1739-1742
 27. **Ford D, Easton DF, Stratton M, et al.** Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet* 1998;62:676-689
 28. **Roa BB, Boyd AA, Volcik K, Richards CS.** Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. *Nat Genet* 1996;14:185-187
 29. **Oddoux C, Struewing JP, Clayton CM, et al.** The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individual is approximately 1%. *Nat Genet* 1996;14:188-190
 30. **Eisinger F, Jacquemier J, Charpin C, et al.** Mutations at BRCA1: the medullary breast carcinoma revised. *Cancer Res* 1998;58:1588-1592
 31. **Armes JE, Egan AJ, Southey MC, et al.** The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. *Cancer* 1998;83:2335-2345
 32. **Johannson OT, Ranstam J, Borg A, et al.** Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. *J Clin Oncol* 1998; 16:397-404
 33. **Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al.** Familial invasive breast cancers: worse outcome related to BRCA1 mutations. *J Clin Oncol* 2000;18:4053-4059
 34. **Chabner E, Nixon A, Gelman R, et al.** Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. *J Clin Oncol* 1998;16:2045-2051
 35. **Gaffney DK, Brohet RM, Lewis CM, et al.** Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. *Radiother Oncol* 1998; 47:129-136
 36. **Rubin SC, Benjamin I, Behbakht K, et al.** Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. *N Eng J Med* 1996;335: 1413-1416
 37. **Verhoog LC, Bern EM, Brekelmans CT, et al.** Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. *J Clin Oncol* 2000;18:119-124

국문초록

한국의 젊은 여성유방암 환자에서 BRCA 배선유전자 돌연변이는 예후인자인가?

순천향대학교 의과대학 방사선종양학교실*, 외과학교실[†], 예일대학교 의과대학 치료방사선과학교실[‡]

최두호* · 이민혁[†] · Bruce G. Haffty[‡]

목적: 한국인 젊은 여성 유방암 환자에서 유방암 유전자 (BRCA)가 예후인자가 될 수 있는지 알아보기 위하여 본 연구를 시행하였다.

대상 및 방법: 대학병원에서 치료를 받은 환자 중에서 유방암이나 난소암의 가족력과 관계없이 40세 이하의 환자를 선택하였다. 환자의 나이는 18~40세이었고 중앙값은 34.5세이었다. 환자의 말초혈액에서 림프구를 모아 DNA를 추출하였으며 BRCA1과 BRCA2의 모든 염기 중에서 기능과 관계 있는 부위의 DNA를 직접염기서열 결정 방식으로 검사하였다. 조직표본 검사가 가능한 환자는 면역화학조직검사를 시행하였다.

결과: 60명의 환자 중에서 유방암 발생과 직접 관계가 있는 돌연변이가 11개(18.3%) 있었고(BRCA1 6명, BRCA2 5명), 의미를 알기가 곤란한 돌연변이가 7개 있었으며 반 수 이상의 돌연변이는 이제까지 보고되지 않은 것이었다. 그리고 대부분의 돌연변이 환자는 유방암이나 난소암의 가족력이 관찰되지 않았다. 유방암 유전자 돌연변이 환자는 한 명도 치료의 실패가 없었으며 한 명에서 반대측 유방암이 발생하였다. 7년 무병 생존율은 돌연변이 환자에서 50%, 돌연변이와 관계가 없는 환자에서 79%이었고 차이는 없었다. BRCA 관련 종양에서 에스트로젠, 프로세스테론 수용체 음성의 비율이 높았으며 조직학적 분화도가 낮았으나 예후는 비교대상에 비해 나쁘지 않았다.

결론: 한국의 젊은 여성 유방암 환자는 예후가 인자가 있어도 재발률이 낮았으며 유전자 돌연변이 이환율이 높았으나 암의 발현율은 상대적으로 낮은 것으로 추정되었다. 이 결과를 확인하기 위해 더 많은 환자 집단과 오랜 추적기간의 연구가 필요하다.

핵심용어: BRCA 돌연변이, 젊은 여성 유방암, 예후인자, 한국인